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Introduction
Palpable thyroid nodules are found in about 5% of 
world population in non-endemic areas with right iodine 
supplement, with a higher correlation with sex (prevalence 
in women), age, abnormal intake of iodine and ionizing 
radiation exposure (1-3). Thyroid nodules are a common 
incidental finding during routinely ultrasound (US) exams 
unrelated to thyroid gland in the healthy adult population 
with a prevalence of 20–76%. The majority of thyroid 
nodules are benign (>95%) and as long as they do not cause 
associated symptoms like dyspnea, dysphagia, hoarseness, 
hyperthyroidism or cosmetic problems, they do not need 
any treatment (1,4). Beside malignant nodules, treatment 
should be considered even for growing or large nodules 
(>4 cm) and in presence of clinical symptoms or cosmetic 
problems. Surgical procedures such as radical thyroidectomy 
or hemithyroidectomy have been considered as the gold 
standard, even though associated with high, sometimes 
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permanent, risks of complications (bleeding, infection, 
lesion of recurrent laryngeal nerve, large neck scar, and 
hypothyroidism), leading patients to a long-term drug 
treatment with controversial efficacy. In addition, due to the 
request of general anesthesia, surgery may not be indicated 
for all patients (2,5-7). More recently, in the radiological 
field, new non-invasive procedures have been developed as 
alternative to surgery (8-19). The aim of this review, based 
on newly revised guidelines, is to provide some information 
regarding the basic principles, indications, materials, 
techniques and results of mini-invasive procedures or 
treatments for thyroid nodules.
Thyroid fine-needle aspiration biopsy (FNAB)
Today, FNAB represents the gold standard for the diagnosis 
of the nature of thyroid nodules due to its safety, reliability, 
low costs and high tolerability by the patients (3,20). 
According to the newly reviewed guidelines for thyroid 
nodules (<5 mm), US monitoring is always recommended. 
FNAB is indicated in presence of large nodules (≤5–10 mm), 
with dubious US features associated to pathologic 
lymphnodes, extrathyroidal growth, personal or familiar 
history of thyroid cancer, and dubious clinical or imaging 
findings. In addition, FNAB should be performed in case 
of (I) nodules (>10 mm) showing frankly benign features; 
(II) nodules (≥20 mm) with spongiform, iso-hyperechoic or 
predominant (>50%) cystic aspect in absence of suspicious 
US findings; (III) in presence of progressive increase in 
size. Exclusion criteria include presence of hot nodules 
on scintigraphy and/or patients with severe coagulation 
disorders. US guidance makes FNAB safer and is now 
considered mandatory, allowing real-time control of 
the tip of the needle when approaching the target areas 
avoiding the vascular structures (1,3,21-23). Five cytologic 
diagnostic categories are considered for the diagnosis of 
thyroid nodules (1): nondiagnostic, benign, indeterminate, 
suspicious for malignancy, and malignant. 
Technique and complications
For all interventional procedures on the thyroid gland, 
the patient is on the prone position, with a pillow under 
the shoulders allowing hyperextension of the neck. The 
neck is cleansed with betadine or alcohol. Subsequently, 
local anesthetic is administered. FNAB is performed using 
needles of variable caliber (ranging from 21 to 27 G) 
usually attached to a 10 cc syringe. In rare cases of cystic 
nodules, where the colloid content is too dense, thicker 
needles are employed (up to 18 G). While entering into 
the nodule, the tip of the needle is continuously visualized 
by the operator under US-guidance. With or without 
aspiration, depending on the structure and vascularization 
of the nodules, the needle is moved to and fro of some 
millimeters to remove cells and, in the end, the material 
extracted is fixed in alcohol or dried air and sent to the 
cytopathologist (1-3) (Figure 1). Low rates of complications 
are described in literature, when the procedure is 
performed by expert operators, and include bleeding with 
risk of cervical hematoma, local infections and vasovagal 
syncope. Proper use of antiseptics, US assistance (for 
identification of intra and extra-gland vascular structures) 
and the manual compression of the entry site may help 
reduce the likelihood of complications (3,24-29). Still 
controversial is the use of antithrombotic agents to reduce 
the risk of post-procedural bleeding. The cause is that the 
Figure 1 FNAB procedure in a patient with multinodular goitre. (A) US images of thyroid show three hypo-echogenic nodules (*); (B) 
US-guided FNAB of one nodule. The needle (white arrow) with its tip perfectly inserted inside the lesion is shown. FNAB, fine-needle 
aspiration biopsy; US, ultrasound.
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antithrombotic agents can probably lead to major cardiac 
and cerebrovascular accidents (3,27-29). Severe coagulative 
deficits may represent a contraindication to FNAB. Despite 
Abu-Yousef et al. reported only 2 hematomas in 593 patients 
submitted to antithrombotic therapy vs. 4 events of bleeding 
in 449 patients not taking antithrombotic medications, it 
is suggested, whenever applicable, to suspend or modify 
the antithrombotic medication after consulting with the 
clinician (3,26,27).
Results
The superiority of US-guided FNAB in terms of adequacy 
of the cytological material obtained, possibility of false 
negative results, sensitivity and specificity has been 
demonstrated in several studies. In 9,683 patients, Danese 
et al. found low rates of cytologically inadequate material 
(3.5% vs. 8.7%) using US-guided FNAB, experiencing an 
increase in the percentage of sensitivity, specificity, and 
global diagnostic accuracy (97.1% vs. 91.8%, 70.9% vs. 
68.8% and 75.9% vs. 72.6%, respectively). They reported 
only 1% of false-negative results vs. 2.3% without US 
assistance (30). Another study carried out by Can et al. 
demonstrated a statistically relevant low rate of inadequate 
cytologic material after US-guided FNAB (P<0.01). In 
fact they observed 27.2% of inadequate cytologic results 
in nodules aspirated by palpation (in 202 patients) vs. 
12.5% in those aspirated under US-guidance (184 patients) 
with a sensitivity of 100% for both procedures (31). In 
their experience, Deandrea et al. demonstrated that 52% 
of histologically malignant nodules could be detected 
only thanks to US assistance, concluding that manually 
guided FNAB is not feasible in non-palpable nodules and 
not so accurate in a multinodular goiter (32). Another 
study conducted by Wu presented satisfying results in 
terms of sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and accuracy 
(100% vs. 96%, 86% vs. 50%, 97% vs. 98, 100% vs. 33% 
and 97% vs. 94%, respectively). The author reported 1% 
of non-diagnostic material vs. 7% in 100 patients submitted 
to US-guided FNAB vs. 100 patients who underwent 
manual FNAB. All procedures had been performed by 
the same pathologist (33). Overall, US-guided FNAB 
provides satisfying results in terms of sensitivity, specificity, 
PPV, NPV and accuracy with low rates of complications, 
particularly when performed by expert operators 
(20,21,23-35). Moudgil et al. performed US-FNAB on 86 
thyroid nodules in 70 children. Ninty point seven percent of 
the diagnostic procedures showed good correlation between 
cytopathology and pathology in patients undergoing surgery 
(93.1%), without false positive or false negative results for 
malignancy. These results are quite satisfying when we 
consider that the rates of malignant nodules in children are 
higher than in adults (35).
Percutaneous ethanol injection (PEI)
PEI is a mini-invasive technique consisting in the 
introduction of ethanol into the tissues. The consequence 
is a thrombosis of small vessels associated at inflammatory 
reaction. The resulting coagulative necrosis followed 
by fibrosis leads to reduction of the dimension of the 
treated lesion (36-38). According to the new guidelines, 
PEI represents the first-line treatment for relapsing and 
symptomatic benign cystic lesions and for nodules with 
an important fluid component. This is due to its safety, 
tolerability, effectiveness in volume reduction, cost 
effectiveness, low rates of recurrence, and short- and long- 
term complications (1,36,39-43). PEI was initially used 
also to treat hyper-functioning nodules or nodular goiters. 
However, compared to surgical treatment or radioiodine 
therapy, high recurrence rates of hyperthyroidism, increase 
in complications, and risk of progressive regrowth make this 
technique indicated only for the treatment of hot nodules 
that cause compressing symptoms. PEI is also used in those 
patients presenting contraindications to or no benefits 
from more effective alternative treatments (1,36,44,45). 
The nodule decrease in volume, albeit of lower entity than 
in cystic nodules, is also described in literature. However, 
the need of repeat treatments brings the potential risk of 
fibrosis of the cervical structures surrounding the treated 
area due to the diffusion of ethanol, making a possible 
surgery treatment more difficult. For all these reasons, 
PEI should be considered for the treatment of benign solid 
nodules only when alternative and more effective modalities 
are not applicable (1,36,46-48).
Technique and complications
A unique protocol to perform PEI has not been defined, 
yet. Still under way are the studies of the right amount of 
ethanol to be injected, the number of repeat treatments 
and the time lapse between them, to achieve maximum 
positive effects with minor number of complications (40). 
The patient positioning is the same as during FNAB. After 
skin sterilization, variable size needles (usually ranging from 
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20 to 25 G) are inserted in the center of the lesion under 
US-guidance with or without previous injection of local 
anesthesia at the entrance site. The cyst or the fluid parts 
of the nodule are almost completely drained by aspiration. 
Ethanol (usually with a concentration ranging from 95% 
to 99%) is slowly injected in the residual cavity through a 
syringe, filling up about 30–50% of the previously aspired 
volume. The procedure lasts about 2 minutes and is always 
monitored with US (ethanol shows an intense echogenicity). 
The solid part of the nodule is avoided. The procedure 
stops in case ethanol leakage is observed out of the nodule 
or if the patient refers severe pain. Some authors inject a 
saline solution or lidocaine during final withdrawal of the 
needle at the end of the procedure (36,40-50). Usually, PEI 
is a well-tolerated and safe technique. Diffusely described 
and not common complications are represented by local 
pain, dizziness, local hematoma, or complications related to 
ethanol extravasation from the nodule (recurrent laryngeal 
nerve palsy, peri-glandular fibrosis). More severe but 
rare complications include ethanol-related larynx or skin 
necrosis, Graves’ disease, Graves’ orbitopathy, Horner’s 
syndrome. One case of Plummer adenoma has also been 
described in literature (36,40,50-53). 
Results
The effectiveness of PEI in the treatment of symptomatic 
cystic or relapsing cystic lesions and of mixed nodules with 
a predominant fluid content has been largely described, 
so much to be considered by the guidelines the first-line 
option due to its safety, cost-effectiveness (1,36,39-43) 
and low potential risk of impairing the thyroid function. 
In a preliminary randomized trial (including 20 patients 
with predominantly cystic thyroid nodules divided 
into two groups) and in a prospective study (including 
32 patients with the same nodule characteristics), Verde 
et al. demonstrated significant effectiveness in nodule 
volume reduction (>50%), at 12-month follow-up, in 
80% patients treated with ethanol injection after fine 
needle aspiration of the fluid component, without relevant 
side effects (54). Zingrillo et al. treated 43 patients with 
relapsed cyst after two aspirations or patients with an 
inefficient aspiration procedure due to the viscosity of the 
fluid material. They showed an impressive reduction in 
the volume of the cyst (91.9%±11.4%) in 93% of patients 
at 5-year follow-up with an additional 5% increased rate 
of success after one retreating procedure. The patients 
reported disappearance of related symptomatology and 
only mild pain was described as complication (42). Also 
Bennedbaek et al. described “curative” volume reduction 
in recurrent thyroid cyst treated with PEI equal to 82% 
(vs. 48% treated only with cyst aspiration and isotonic 
saline solution). They reported a lower number of sessions 
(single session in 64% vs. 18%) and low rates of side 
effects consisting only in moderate/severe pain and one 
case of transient dysphonia (48). Several studies correlate 
the number of PEI sessions with the dimension of the 
cystic volume. For example, a recent work by Negro et al. 
demonstrates a significantly (P<0.05) higher number of 
PEI in the group with larger cystic lesions (>30.0 mL) with 
the smallest percentage in volume reduction after the first 
treatment (P<0.05). Conversely, the smallest cystic lesions 
(<10.0 mL) had a significant volume reduction only after 
one PEI session in a high number of cases (85.7%). Even 
in these cases, the rate of side effects consisting of mild/
moderate pain was very low (17.4% and 4.1%, respectively) 
(50,55,56). Baek et al. did not find significant differences 
in volume reduction, symptomatology and cosmetic scores 
comparing the treatment with PEI and radiofrequency 
ablation (RFA) in cystic nodules, and considered the first as 
a better technique due to cost-effectiveness and low risks 
of major complications (40). The same considerations are 
shared by other authors (Sung et al.) and can be found in 
the revised guidelines (1,39,56,57). 
Concerning the treatment of solid thyroid nodules, 
though many non-randomized and a few randomized 
trials demonstrate a decrease in nodule volume after PEI 
treatment, an increased rate of complications is described, 
with only a limited improvement observed for repeated 
treatments (44,58,59).
Using PEI, Kim et al. found statistically significant 
differences (P<0.01) between nodule volume reduction in 
cystic lesions and solid lesions (59). For this reason, PEI is not 
the first choice in the treatment of solid thyroid nodules and 
is reserved to those patients who present contraindications to 
other more effective treatments (1,44,46-48,60-62).
PEI can find indication in hyperfunctioning or goitre 
thyroid nodules. As secondary treatment choice, it is 
employed in patients with solid lesions, due to short-term 
volume reduction and thyroid-stimulating hormone (TSH) 
serum suppression in many cases, with an high rate of 
recurrence (1,44,61,62).
Some authors conducted meticulous search on the 
effectiveness of PEI in the treatment of recurrent papillary 
thyroid carcinoma, but their investigations are limited 
by too short-term follow-up studies. A recent research 
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published in the current year by Kim et al., based on the 
treatment with PEI of 41 recurrent lesions that could not 
undergo repeat surgery, and long-term follow-up (minimum 
60 months), shows a good rate of size reduction (58.5%) 
and statistically significant index of no-response lesions 
depending on age and size. Finally, the authors conclude 
considering PEI as a secondary treatment option with some 
limitations, to be used for patients who cannot be submitted 
to or refuse repeat surgery, and in lesions with a diameter 
>10 mm (51).
Laser thermal ablation (LTA)
LTA is a quite new mini-invasive technique that, causing 
coagulative necrosis, can significantly reduce thyroid 
nodule volume as well as symptoms and cosmetic problems. 
The technique uses heat generated from laser light. The 
resulting increase in local temperature (>60 ℃) leads to 
necrosis, followed by fibrosis and consequent reduction of 
the lesion size. The new guidelines provide evidence of the 
effectiveness, safety and well tolerability of this technique 
as alternative to surgery. LTA reduces large benign nodules 
that cause symptoms or cosmetic problems without 
determining changes in thyroid function or autoimmunity 
(1,35,63-67).
Technique and complications
After putting the patient in the typical position for thyroid 
procedures (hyperextension of the neck with a pillow under 
the shoulder), skin disinfection is performed, followed 
by local anesthetic injection into the subcutaneous tissue 
and the thyroid capsule. Silica optical fibers are inserted, 
under US-guidance, into the lesion through one to four 
21 G needles positioned along the longitudinal major 
nodule axis, at a distance of 10–15 mm from each other 
depending on the nodule size. Energy is generated by 
Nd:YAG (neodymium: yttrium aluminum garnet) or by 
laser diode and delivered into the lesion for 5–15 minutes, 
until an inhomogeneous hyperechogenic area appears in 
place of the nodule. In case of large nodules, the “pull 
back technique” is employed; consisting in the retraction 
of the fibers of 1.0–1.5 cm. LTA is a safe procedure with 
low rate of side effects. Minor complications include 
cervical swelling and pain, local bleeding, hematomas and 
fever. More rarely, major side effects were observed such 
as changes in thyroid function or autoimmunity, laryngeal 
dysfunction, vocal cord palsy, recurrent nerve lesion or 
cervical structure injuries (1,35,45,65-75).
Results
In agreement with the guidelines in endocrinology, non-
randomized, randomized and multicentre retrospective 
studies confirm the effectiveness, safety and clinical efficacy 
of LTA in the treatment of symptomatic cold thyroid 
nodules in terms of volume reduction and improvement 
in symptoms and cosmetic problems (1,35,62,64,65,72). 
Valcavi  et  a l .  reported a reduction of  about 50% 
(47.8%) in nodule volume at 3-year follow-up studies in 
122 patients. Changes in thyroid function were not 
observed and symptoms and cosmetic signs improved in 
73.0% and 71.3%, respectively, with a worsened condition 
for both inferior to 5%. Only 9% of nodule regrowth and 
low rates of side effects were observed (2 patients showed 
delayed laryngeal dysfunction; alterations of the thyroid 
function were observed in 4 patients) (68). Similar results 
were reported also in a randomized trial work by Døssing 
et al. carried out in 78 euthyroid patients at 1 year follow-
up, with a 51% rate of decreasing nodules, disappearance 
of symptoms and cosmetic complaints in 84% and 72% of 
patients. Only moderate pain, lasting 4 days, was reported 
as side effect with no modification in thyroid function (69). 
Gharib et al. produced two prospective randomized 
studies where patients with cold thyroid nodules, treated 
with two different kinds of laser source (Nd:YAG and 
diode), showed similar and significant reduction in nodule 
volume (44% and 43%, respectively). They also observed 
reduction of local symptoms in most of the patients at 6- 
and 12-month follow-up. These studies were compared 
with LT4 suppression therapy and with a control group 
and both did not present significant changes in nodule 
diameters and symptoms (46). A recent study conducted 
by Pacella in 1,871 patients showed statistically relevant 
(P<0.001) improvement after LTA treatment in terms of 
volume reduction (mean 72.11%, more significant in mixed 
nodules where it reached 79.7%), related symptoms (from 
49% to 10%) and cosmetic signs (from 86% to 8%). The 
complication rate was low (only 0.9%) and no thyroid 
function or autoimmunity changes were reported (64). 
Concerning hyperfunctioning thyroid nodules and 
multinodular goitre, LTA does not represent the first choice 
treatment because radioiodine therapy and surgery provide 
better results. Although some investigations carried out on 
small series observed recovery of the physiological thyroid 
function and disappearance of hyperfunctioning areas at 
radioisotope scan in patients treated with LTA, in other 
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studies the use of this technique was deemed unsatisfactory. 
Repeat treatments were necessary to normalize the TSH 
serum levels and the technique did not prove as cost-
effective as radiation therapy (35,44,62,69,73-75). In a 
randomized trial, Døssing et al. compared the results 
between a single LTA treatment and radioiodine therapy on 
30 solitary hot nodules. Even though LTA showed similar 
volume nodule reduction, the normalization of serum TSH 
was obtained in 50% of patients alone (73). In conclusion, 
LTA may be considered as a therapeutic option in small, 
solitary and small hyperfunctioning nodules in patients 
with contraindication or pharmacological interaction to 
radioiodine therapy (1,35,44,62). Several studies compared 
LTA to RFA and provided different results on their efficacy 
in the treatment of benign thyroid nodules. In favour of 
LTA is a recent study performed by Pacella et al. where in 
601 nodules (449 treated with LTA and 152 with RFA), a 
slightly superior nodule shrinkage was observed in the LTA 
group, particularly in large nodules. The same incidence 
of complications was observed (74). The treatment of 
unresectable or recurrent malignant thyroid cancer is poorly 
described in literature. The few investigations available are 
based on low numbers of patients and short-term follow-up 
studies. Radioiodine therapy and surgery remain the gold 
standard in these cases. LTA can be considered as palliative 
in primary thyroid carcinoma and as an alternative in the 
local control of small recurrent papillary carcinoma (44). 
Zhou et al.  have recently published a work where 
27 recurrent papillary carcinoma lesions (with diameter 
<15 mm) were treated with LTA. In their experience, the 
lesions showed great reduction in volume (7.5±2.8 mm 
and 105.4±114 mm3 to 0.4±1 mm and 0.8±2.4 mm3 at the 
final follow-up). Three patients needed a second treatment 
session due to incomplete ablation detected by contrast-
enhanced ultrasound (CEUS). No patients presented 
vascular signals at color-Doppler exam. Absence of 
vascularization was also appreciated at CEUS examination. 
No major complications were described (75).
RFA
RFA is a new minimally invasive technique developed 
in the last years. Applied also for the treatment of bone 
and abdominal tumors, RFA is based on the movement 
of ions determined by an electric field, which in turn is 
produced by an external radiofrequency generator. The 
latter is connected to an electrode needle that determines 
an increase in local temperature (between 60 and 100 ℃). 
The result is a coagulative necrosis of the area around the 
needle. RFA can be performed in the treatment of benign 
thyroid nodules which cause symptomatology and cosmetic 
problems. It can also be applied in patients with recurrent 
thyroid cancers who present contraindications or simply do 
not acconsent undergoing surgery (1,2,4,35,44,76-81). At 
present time, this technique is not recommended for the 
treatment of primary thyroid cancer because so far there is 
not scientific evidence on its effectiveness (1,4,82,83).
Technique and complications
With the patient in the supine position and hyperextended 
neck, the skin is disinfected and local anesthesia performed. 
The latter is preferred to general anesthesia because the 
patient must be constantly monitored. Onsets of pain or 
voice alterations, in fact, are events that require interruption 
of the procedure. Local anesthesia is injected in sub-
cutaneous tissues and under the thyroid capsule. RFA can be 
carried out with two different techniques both under US-
guidance, using two different types of needles. The “fixed 
ablation technique” consists in the introduction of a 14 G 
multitined expandable needle (with 4–9 expandable hooks) 
along the long axis of the nodule (cranio-caudal approach). 
The “moving shot technique” consists in the introduction 
of an internally cooled needle with variable diameter 
(17–19 G), length (7–15 cm) and active tips (ranging 
from 0.5 mm to 2 cm). The needle is inserted through 
the isthmus (trans-isthmic approach), starting from the 
middle to the lateral direction, to reach the nodule which is 
divided in different small hypothetical zones, each ablated 
by moving the tip of the needle from the deepest position 
upwards to the most superficial part of the nodule. The 
“moving shot technique” presents some advantages over the 
“fixed ablation technique”. The latter provides a spheroidal 
ablation area, while the “moving shot” technique allows 
treatment of ellipsoidal areas (that represent the most likely 
form of thyroid nodule in routine practice). Moreover 
reduces the risk of complications and side effects, due to 
the minor exposure and the constant US monitoring of the 
laryngeal recurrent nerve that runs in the “danger triangle” 
situated between trachea, esophagus and thyroid gland. In 
addition, the trans-isthmic approach allows stability of the 
needle and prevents its involuntary movement even if the 
patient talks or coughs. Finally, the ablation of the lesion is 
confirmed by the US appearance of a hyperechogenic area 
associated to a sudden increase of impedence registered 
by the external generator (1,4,35,44,84-90) (Figure 2). 
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Complications and side effects are similar to those observed 
during other interventional procedures. Low rates of 
major complications are described when the procedure is 
performed by an expert team. Several sensitive structures 
surround the thyroid gland: recurrent laryngeal and vagus 
nerve, cervical ganglion, esophagus, trachea and important 
vessels. However, so far, no injury of vessels, esophagus and 
trachea has been described in literature. Hydrodissection, 
consisting of 5% dextrose solution injection between the 
peripheral nodule area and surrounding critical structure, 
has been demonstrated effective to reduce clinical 
complications (91). Major complications were represented 
by voice changes determined by an injury of the laryngeal 
or vagus nerve (usually transient and not lasting more than 
3 months), brachial plexus damage, nodule rupture and rare 
changes in thyroid function (above all transient). Minor 
complications included bleeding and subsequent hematoma 
(lasting few weeks and reduced by post-procedural neck-
compression), pain (it is the most frequent side effect and 
was generally controlled by stopping the ablation or using 
pain-killers for 2–3 days post-treatment), skin burns around 
the puncture sites, and infection (for this reason, antibiotics 
must always be administered before RFA), cough and 
vomiting (4,60,91-94). 
Results
Several studies demonstrate the effectiveness, safety and 
clinical efficacy of RFA in terms of nodule volume reduction, 
improvement in symptoms and cosmetics in the treatment 
of both benign cold and hyperfunctioning thyroid nodules 
(resolving thyrotoxic status in hot nodules). The newly 
Figure 2 RFA procedure of a benign thyroid nodule. (A) US image of a thyroid nodule of the right lobe in a 47-year old woman; (B) RFA 
of the nodule: the needle inside the lesion (white arrow) with the appearance of a hyper echogenic area represented the ablated area; (C) US 
appearance of thyroid nodule after RFA treatment at 1 month follow-up. Reduction in nodule volume can be appreciated; (D) US image 
shows a significant shrinkage of the benign nodule compared to image (A) and (C) at 6-month follow-up study. +, the cursors to measure the 
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reviewed guidelines also confirm RFA as an alternative 
to surgery and radioiodine therapy. A systematic review 
carried out by Fuller et al. in 2014 analyzed nine studies 
inclusive of 292 nodules (both cold and hot) in 284 patients 
with a mean of 1.05 session treatment performed for 
each nodule. The reviewed studies included 3 single arm 
observational investigations employing RFA alone, 2 single 
arm observational studies performing RFA before or after 
PEI, 2 randomized controlled trials comparing RFA to a 
control group, 1 randomized prospective trial comparing 
the effectiveness of one to two RFA sessions treatments 
and 1 randomized, prospective trial confronting RFA to 
PEI. The longest follow-up was 12 months. These studies 
demonstrated a statistically significant important reduction 
in mean volume of cold (−9.67 mL, ranging from −15.04 
to −4.30 mL) and autonomously functioning nodules 
(−16.14 mL, ranging from −24.28 to −7.99 mL) after RFA. 
After the treatment, symptoms and cosmetic problems had 
a statistically significant improvement as well. Four trials 
using VAS for symptoms showed a mean improvement 
of −2.89 points (ranging from −2.51 to −3.28 points) 
and five trials presenting objective four-point scale for 
cosmetic problems showed a mean improvement of 
−2.02 points (ranging from −1.69 to −2.35 points). Even 
in those studies, using a combined symptom-cosmetic 
0 to 6 point scale, changes were statistically significant, 
with a mean improvement of −2.96 points (ranging from 
−2.66 to −3.25 points) (95). In benign hyperfunctioning 
thyroid nodules, improvement in gland function was also 
appreciated and associated to reduction of antithyroid 
medication. These studies showed low rate of complications 
and side effects (3.9%). Two major complications (1 vocal 
cord palsy lasting 1 month after treatment and 1 diffuse 
glandular haemorrhage) and 11 minor complications 
(hematoma, slight-moderate pain, fever, edema and low-
grade skin burn at the site of electrode insertion) were 
noticed (4,57,88-90,92-97) and were comparable to the rate 
of complications observed in another large study performed 
by Baek et al. (3.3%) (91). Lim et al. showed an important 
shrinkage of nodules with a mean of 93.5%±11.7% in 
111 patients at longer follow-up series (about 4 years) with 
a mean session treatment of 2.2±1.4. They noticed a faster 
and better reduction in volume in predominantly cystic, 
compared to solid nodules, and obtained a statistically 
significant improvement in symptoms and cosmetics 
(P<0.001) (96). The rate of regrowth superior to 50% 
was low (5.6%) depending on an undertreating of the 
peripheral nodule portion that could lead to more sessions 
of treatments and a relapse of increase in thyroid function 
(according to other authors) (85,98,99). Deandrea et al. (98) 
showed at 6-month follow-up study, a significant volume 
reduction in patients treated with RFA (15.1±3.1 vs. 
4.2±2.7 mL; P<0.0001), compared to patients who 
underwent observation alone (14.4±3.3 vs. 15.2±3.5 mL). 
Furthermore, both cosmetic and compressive symptoms had 
a statistically significant (P<0.001) improvement (3.6±0.5 vs. 
1.7±0.4 and 3.6±1.9 vs. 0.4±0.7, respectively) compared 
to the other group without reporting any complications 
or changes in thyroid function (100). In a recent study in 
108 patients with single or multiple nodules, Tang et al., 
showed a statistically significant decrease in nodule volume 
(P<0.05) after RFA with volume reduction ratio (VRR) 
at 1- and 3-month follow-up of 64.12% and 85.54%, 
respectively (2). Sung et al. treated 44 hot nodules (23 with 
a toxic nodule and 21 with a pretoxic nodule) that refused 
or presented contraindication to surgery or radioiodine 
therapy (99). The mean follow-up was 19.9±12.6 months. 
They observed an important shrinkage of nodules already at 
1 month and even greater during the last follow-up passing 
from a mean volume of 18.5±30.1 mL to a mean volume of 
4.5±9.8 mL (P<0.001). A significant improvement of thyroid 
serum hormon was also observed and, at scintigraphy, 
35 nodules showed loss of overall uptake. Nine nodules 
showed decreased uptake at the last follow-up. Related 
symptoms and cosmetic problems were also found 
significantly improved during the last follow-up study. 
No major side effects were found. Different studies 
compared RFA with LTA resulting in higher efficacy of 
RFA in providing nodule volume decrease (1,100,101). 
However, recent studies performed on a number superior to 
1,500 patients reported that both techniques had similar 
uptake decrease (1,98). RFA can be used for locoregional 
control of cancer or improvement of cancer-related 
symptoms in patients with recurrent thyroid cancer 
who present high surgical risk and refuse repeat surgery. 
RFA of recurrent thyroid cancer in the neck resulted in 
a mean volume reduction of 56% to 93% with 42% to 
58% of nodules completely disappearing and 64% of 
patients experiencing symptom improvement and serum 
thyroglobulin concentration decrease. Long-term follow-up 
data have not been published, yet (88,102,103). According 
to the Korean Society of Thyroid Radiology and confirmed 
by a 2015 Italian report, even in absence of long-term 
follow-up studies, RFA is indicated in the treatment of 
recurrent thyroid cancers in patients with high surgical 
risk or refusing repeat surgery. In literature, the mean 
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tumor volume reduction described presented a variable rate 
ranging from 50.9% to 8.4%. The rate of tumor complete 
disappearance ranged from 25% to 94% of cancers with an 
improvement in therapeutic success and symptoms ranging 
from 75% to 97% and 64%, respectively. Moreover, 
in many patients a decrease in serum thyroglobulin 
concentration was described (88,102-111). A recent meta-
analysis made by Suh et al. compared the effectiveness and 
safety of RFA and PEI for the treatment of total sample 
size of recurrent thyroid cancers in 270 patients with a 
VRR ≥50% rate of 100.0% after RFA and of 89.5% after 
PEI associated to a rate of complete disappearance of the 
nodules of 68.8% and 53.4%, respectively. The RFA rate 
of recurrence of 0.0% and 2.4% concerning PEI and also 
the number of sessions were lower in patients treated with 
RFA (less than 1.3 vs. greater than 2 in PEI). All this rates 
were however no statistically significant (110). Based on 
the guidelines, RFA is not indicated as first-line therapeutic 
option due to a low number of evidence (1,92). Despite 
this, a recent study by Zhang et al. reported no residual or 
recurrent tumor after RFA at 12- and 18-month follow-
up in 92 patients with low-risk papillary thyroid micro-
carcinomas (PTMC). In addition, no suspicious metastatic 
lymphnodes were detected and US-guided biopsy confirmed 
the absence of residual or recurrent cancer areas. No major 
complications were described during this study (111).
Percutaneous microwave ablation (PMWA)
PMWA is a new technique used to treat thyroid nodules. 
Due to its novelty, the technique is still scarcely described in 
literature. Used for the treatment of tumors of other nature, 
it uses the rotation of molecules produced from microwave 
energy to increase the local kinetic energy thus producing 
a rapid increase of local temperature inside the tissues. The 
result is the ablation of the target tissue (112-119).
Technique and complications
The patient is in the supine position with neck extension. 
The material needed is a microwave generator, a flexible low-
loss coaxial cable and a cooled shaft antenna. The generator 
produces 1–100 W of power at 2,450 MHz, releasing energy 
in pulse or continuous way. The antenna is a 16 G needle 
and is composed by polytetrafluoroethylene. It is 3–5 mm 
long. Distilled water is conveyed inside the antenna shaft to 
cool it. After skin disinfection and local anesthesia the needle 
antenna is positioned along the long axis of the nodules 
under US-guidance. Delivered energy usually ranges from 
30 to 50 W and the ablation zone appears like a hyperechoic 
area, similarly to RFA. The complete ablation is obtained 
moving the tip of the needle. Several authors recommend 
compression of the neck to avoid the formation of hematoma. 
Hydrodissection techniques can also be used to increase the 
distance between the target lesions and the critical structures 
surrounding the thyroid (112,113). Complications and side 
effects are the same as in the other ablation techniques and 
include hematomas, different degrees of pain intensity, 
transient voice changes, recurrent laryngeal nerve injury, skin 
burns and thyroid dysfunction (115-119). 
Results
Only a few studies report the effectiveness of PMWA in the 
treatment of benign solid thyroid nodules. The described 
volume reduction rate ranges from 45% to 65% in follow-up 
studies lasting up to 12 months. Improvement of symptoms 
and cosmetic problems and no significative changes in 
thyroid function were observed (116,117). Recent studies 
included an important number of patients. Liu et al. treated 
with PMWA 474 benign thyroid nodules in 435 patients 
and observed a significant decrease in volume (90% is the 
mean rate of final volume reduction at 1-year follow-up). No 
major complications were described (112). Wu et al. treated 
121 benign thyroid nodules and observed statistically 
significant (P<0.001) improvement in the decrease of nodule 
volume, symptoms and cosmetic problems at 1-year follow-up 
with a low number of complications (2 patients had hoarseness 
recovered within 2 months; 2 patients showed a slight 
skin burns; 1 case developed Horner syndrome, recovered 
within 2 months) (113). Yue et al. reported a significant 
shrinkage of nodules treated with PMWA in 110 patients 
at 1 year (ranging from 12.6±15.1 to 3.2±5.7 mL). Sixteen 
patients had recurrence 12 months after treatment and the 
authors put this in relation to initial large volume of the 
nodule, presence of more irregular blood vessels and lower 
energy delivered (116). Only one study describes the use of 
PMWA in the treatment of 17 patients with 23 recurrent 
thyroid cancers with high rate of mean tumour volume 
reduction (91%) at 18-month follow-up. Thirty point four 
percent of patients showed complete disappearance of tumors 
and 52.2% residual small scar-like lesions (119).
High intensity focused ultrasound (HIFU)
HIFU is a new mini-invasive technique that induces 
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thermal coagulative necrosis inside the tissues due to high 
intensity US beam focalized into a target lesion, without 
skin penetration by devices. Several significations are 
required to perform the complete ablation of the lesions 
considered the small ablative volumes provided by each 
single sonication. This may lead to prolonged duration of 
the treatment (120-126). 
Technique and complications
Under conscious sedation, the patient is placed in a supine 
position with hyperextended neck. According to literature, 
only one US-guided device for the treatment of thyroid 
nodules is commercially available, namely the EchoPulse® 
(Theraclion SA, Malakoff, France). This device has two 
independent US systems, one for US-guidance and the 
other attached to the transducer generating the focalised US 
beam. The focal point is always put in the centre of the US 
image where the target area always appears as hyperechoic. 
The device is setted to limit automatically its power when 
approaching the sensible structures around the nodule. 
Maintenance of safety margins is always recommended to 
avoid complications as described in literature. The lesion 
is divided into different voxel areas of treatment. Each 
sonication lasts from 4 to 8 seconds with 20 to 40 seconds 
of cooling interval (7,123-126).
Results
A low number of patients were treated with HIFU and a 
recent systematic review presented by Lang et al. identified 
five original studies which showed nodule volume reduction 
rate ranging between 45% and 68%, after a single session of 
HIFU ablation, with varying results depending on nodule 
size and length of follow-up (7). An investigation carried 
out in 2017 by Sennert et al. on 19 benign nodules showed 
volume reduction rate of 58% at 3-month follow-up, with 
10 out of 19 patients showing therapeutic success (defined 
as a volume reduction ≥50%) (126). No studies have been 
published, yet, describing the treatment of primary of 
recurrent thyroid cancer.
Conclusions
Treated by surgery alone during the past decades, many 
thyroid nodules nowadays can be treated by means of new 
mini-invasive techniques that are less expensive and present 
lower risks of major complications and side effects over 
surgery. In particular, PEI is in presence of cystic thyroid 
nodules, LTA and RFA in the treatment of both cold and 
hyperfunctioning benign nodules in patients who refuse or 
have contraindications to surgery or radioiodine therapy. In 
presence of recurrent papillary thyroid cancer, PEI, LTA and 
above all RFA can be considered as a valid option in patients 
who cannot undergo surgery. PMWA and HIFU show less 
evidence of effectiveness in the treatment of this kind of 
nodules even if the results published so far are encouraging. 
During the last years, PMWA has importantly developed and 
the last studies have demonstrated similar effects compared 
to RFA. So, PMWA can be considered as a valid alternative 
to the other ablation techniques. Further studies are needed 
instead to confirm the effectiveness of HIFU as treatment of 
choice. At present, the complication rate of HIFU is lower 
than in other techniques, but the rate of volume reduction 
of the nodules is lower. There are also less therapeutic 
indications which represent a limit to its employment.
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